期刊文献+

良性前列腺增生症并发急性尿潴留患者膀胱功能评估 被引量:5

Evaluation of bladder function in patients with acute urinary retention caused by benign prostatic hyperplasia
暂未订购
导出
摘要 目的评估并发急性尿潴留(AUR)的良性前列腺增生症(BPH)患者逼尿肌功能,预测术后疗效。方法对68例并发AUR的BPH患者术前通过尿动力学检查评估下尿路功能,术后行自由尿流率测定评估疗效。结果 53例完成自由尿流率测定的患者最大尿流率(7.3±2.8)mL/s,平均尿流率(3.5±1.7)mL/s,排尿量(189±94)mL。剩余尿小于50 mL者48例,其余5例平均剩余尿118 mL。压力-流率同步测定结果显示,储尿期膀胱功能容量减小、敏感性增高者58例,57例可见逼尿肌不稳定收缩(83.82%)。高顺应性膀胱、逼尿肌收缩乏力者13例。术后61例排尿通畅,7例再次留置导尿7~15 d拔管,4例可以通畅排尿。3例仍不能自主排尿,其中1例行膀胱造瘘,2例间断清洁导尿。结论对于并发AUR的BPH患者术前通过尿动力学检查准确评估下尿路功能,可以预测术后疗效。 Objective To evaluate the function and postoperative effect of bladder in patients with acute urinary retention ( AUR ) caused by benign prostatic hyperplasia (BPH). Methods The function of lower urinary tract and free flow rate in 68 cases with BPH + AUR were evaluated by urodynamic examination. Results Measurements of free urine flow rate in 53 patients showed that Qmax was (7.3±2.8 ) mL/s, Qave was ( 3.5 ±1. 7 ) mL/s, voiding volume (VV) was ( 189±94 ) mL before operation. Residual urine was less than 50 mL in 48 cases ,5 cases with average residual urine was 118 mL. The results of pressure-tlow showed that the capacity of bladder had reduced and bladder hypersensitivity were increased in 58 cases. Detrusor instability was detected in 57 patients (83.82%). The bladder of 13 patients were diagnosed with high compliance and abnormality in contractility of detrusor. After operation 61 cases voided well,7 cases were performed indwelling catheter for 7 - 15 d. Then 4 cases voided well while 3 cases can not urinate yet. Cystostomy was performed in 1 of the 3 patients and clean intermittent catheterization was used in other 2 patients. Conclusion Urodynamic study is very useful for the treatment of patients with AUR secondary to BPH.
出处 《局解手术学杂志》 2013年第2期176-177,共2页 Journal of Regional Anatomy and Operative Surgery
基金 贵州省卫生厅科学技术基金(gzwkj 2011-1-100)
关键词 良性前列腺增生症 急性尿潴留 尿动力学检查 逼尿肌 benign prostatic hyperplasia acute urinary retention urodynamic study detrusor
  • 相关文献

参考文献7

  • 1周占松.良性前列腺增生和慢性前列腺炎的诊断与治疗[J].局解手术学杂志,2011,20(2):115-116. 被引量:2
  • 2Fitzpatrick JM, Desgrandchamps F, Adjali K, et al. Management of acute urinary retention:a worldwide survey of 6 074 men with benign prostatic hyperplasia [J]. BJU Int,2012,109 ( 1 ) : 88 - 95.
  • 3Schafer W,Abrams P, Liao L, et al. Good urodynamic practices: uroflowmetry,filling cystometry, and pressure flow studies [ J ]. Neurourol Urodyn ,2002,21 ( 3 ) :261 - 274.
  • 4Vande Griend JP, Linnebur SA. Inhaled anticholinergic agents and acute urinary retention in men with lower urinary tract symptoms or benign prostatic hyperplasia [ J ]. Ann Pharmacother, 2012,46 ( 9 ) : 1245 - 1249.
  • 5Bhomi KK, Bhattachan CL. Factors predicting the success of a trial without catheter in acute urinary retention secondary to benign prostatic hy- perplasia[ J]. Nepal Med Coll J,2011,13(3) :178 -181.
  • 6Bablumyan A, Kamalov A, Kirpatovski V, et al. Relationship of acute urinary retention, bladder ischemia and metabolic changes in bladder wall and urine during infravesical obstruction due to benign prostatic hyperplasia[J]. Georgian Med News,2011,11 (200) : 18 - 20.
  • 7Wagenlehner FM, Bescherer K, Wagenlehner C, et al. Urodynamic impact of acute urinary retention in patients with benign prostatic hyperplasia: a 2-year follow-up after transurethral resection of the prostate [J]. Urol Int,2011,86( 1 ) :73 -79.

二级参考文献11

  • 1叶章群.良性前列腺增生的诊断和治疗[J].中华老年医学杂志,2006,25(5):390-392. 被引量:48
  • 2周占松,宋波.纳米细菌在泌尿系疾病中的作用[J].重庆医学,2007,36(10):967-968. 被引量:2
  • 3AUA Practice Guidelines Committee.AUA guideline on management of benign prostatic hyperplasia (2003).Chapter 1:Diagnosis and treatment recommendations[J].J Urol,2003,170(2 Pt 1):530-547.
  • 4Roehrbom CG,Bruskewity R,Nickel GC,et al.Urinary retention in patients with BPH treated with finasteride or placebo 4 years[J].Eur Urol,2000,37(5):528-536.
  • 5Eri LM,Tveter KJ.alpha-blockade in the treatment of symptomatic benign prostatic hyperplasia[J].J Urol,1995,154(3):923-932.
  • 6Hutchsion A,Farmer R,Verhamme K,et al.The efficacy of drugs for the treatment of LUTS/BPH,a study in 6 European countries[J].Eur Urol,2007,51(5):207-216.
  • 7Hatzimouratidis K,Hatzichristou D.Phosphodies-terase type 5 inhibitors:the day after[J].Eur Urol,2007,51(1):75-89.
  • 8Brawer MK.Lonidamine:basic science and rationale for treatment of prostatic proliferative disorders[J].Rev Urol,2005,7(7):S21-S26.
  • 9Krieger JN,Nyberg LJr,Nickel JC.NIH consensus definition and classification of prostatitis[J].JMMA 1999,282(3):236-237.
  • 10周健,刘显中,刘德云,闻斌,刘津念,田波,张茂,刘聪颖.2μm激光汽化切割术治疗良性前列腺增生的临床研究[J].重庆医学,2009,38(16):2044-2045. 被引量:7

共引文献1

同被引文献37

引证文献5

二级引证文献20

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部